Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: trofala who wrote (1752)	7/2/1998 10:11:00 AM
From: Sigmund	Read Replies (1) \| Respond to of 1894

Nothing like lots of news especially good news. ACCUMED ANNOUNCES ACCELL CONTRACT CHICAGO, July 2, 1998 - AccuMed International, Inc. (Nasdaq: ACMIC) today announced that a large not-for-profit health maintenance organization has contracted for the AcCell„ Cytopathology System in their cytology laboratories. The AcCell system will be used in support of general cytology and cervical cytology (or Pap) screening programs, according to Paul Lavallee, Chairman and CEO of AccuMed. The health maintenance organization is a large not-for-profit organization serving several million members in 19 states and the District of Columbia. An integrated health delivery system, the HMO organizes and provides or coordinates members' care, including preventive care such as well-baby and prenatal care, immunizations, and screening diagnostics; hospital and medical services; and pharmacy services. As part of its continued efforts to provide the highest quality care to its members, the HMO will be implementing the AcCell system at one of its regional laboratory sites. Over the next several months, the laboratory will be evaluating AcCell's ability to raise the level of efficiency achieved in its cytology department to levels previously unattainable. "We are extremely excited to be working with this prominent organization on this project" said Paul Lavallee, AccuMed's Chairman and CEO. "This HMO represents one of the most quality conscious organizations in the country. This is a perfect place for the AcCell system to demonstrate its true capabilities." Paul F. Lavallee, AccuMed's CEO, noted, "The AcCell Cytopathology System is unique among cytology technologies in that it enhances the work performed by highly trained and skilled cytotechnologists and cytopathologists in the laboratory. In so doing, AcCell streamlines the entire cytology process resulting in enhanced risk and quality management, and reduced costs. AccuMed International, Inc., headquartered in Chicago, is a global advanced diagnostics and information solutions company. AccuMed is an emerging leader in integrated, technology-driven systems that accommodate the clinical laboratory's need to maintain quality while achieving more cost-effective operation. The company manufactures and markets a full line of proprietary, FDA-cleared bacterial microbiology disposable tests and instruments and integrated automated cytopathology systems. Except for the historical information contained herein, the matters discussed in this news release are deemed "forward-looking statements" under federal securities laws that involve risks and uncertainties. Actual results may differ materially from those in the forward-looking statements depending on a number of factors, including, among other things, the ability to maintain long-term relationships with corporate partners, the ability to bring products to market through the regulatory approval process, uncertainty of future profitability, financing requirements, and other factors detailed in AccuMed's filings with the Securities and Exchange Commission. * * * * Visit AccuMed's web site at accumed.com For investor information, contact Darlene Czaja Telephone: (312) 397-7455 FAX: (312) 642-3492 e-mail: ir@accumed.com